OncoMatch/Clinical Trials/NCT05922345
Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
Is NCT05922345 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for non-small cell lung cancer.
To investigate the efficacy of AL2846 capsules in combination with TQB2450 injection or Docetaxel injection in patients with advanced NSCLC who have previously failed immune checkpoint inhibitors (anti-PD-1 monoclonal antibody, anti-PD-L1 monoclonal antibody), regardless of new anti-tumor treatment and early termination of treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: ALK fusion
Excluded: EGFR mutation
Excluded: ROS1 fusion
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — locally advanced or metastatic or recurrent
Failure of platinum-based chemotherapy
Must have received: checkpoint inhibitor — locally advanced or metastatic or recurrent
Failure of...immune checkpoint inhibitors
Cannot have received: other immunotherapy
Previously received other immunotherapy
Cannot have received: tyrosine kinase inhibitor
Research Advance of Small Molecular Targeted Anti-Tumor Agents Tyrosine kinase inhibitors (TKIs)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate major organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify